Literature DB >> 35313549

Risk Factors for the Development of Tuberculosis Among HIV-Positive Adults Under Highly Active Antiretroviral Therapy at Government Hospitals in Amhara Region, Ethiopia.

Awoke Seyoum Tegegne1, Molalign Tarekegn Minwagaw2.   

Abstract

Background: Tuberculosis is one of the leading infectious diseases for people living with HIV. Therefore, the purpose of this study was to investigate factors affecting the development of TB among HIV-positive adults under treatment in government hospitals of Amhara Region, Ethiopia.
Methods: A hospital-based retrospective study design was conducted among 700 HIV-positive adults under HAART in 17 government hospitals in the Amhara region, Ethiopia.
Results: Age of the patients (AOR = 1.122, 95% CI:1.013, 2.234), baseline CD4 cell count (AOR = 0.888, 95% CI: 0.714, 0.945), patients living without their partner (AOR = 1.212, 95% CI: 1.051, 1.123), females under treatment (AOR = 0.786, 95% CI; 0.564, 0.845), non-opportunistic diseases (AOR = 0.865, 95% CI: 0.731, 0.938), patients not disclosed their HIV status (AOR = 1.241, 95% CI: 1.087, 2.341), rural patients (AOR = 1.135, 95% CI: 1.032, 1.453, patient with no education (AOR = 1.125, 95% CI: 1.056, 1.546), low adherence patients (AOR = 1.225, 95% CI: 1.191, 2.453), bedridden patients (AOR = 1.223, 95% CI: 1.131, 1.521), ambulatory patients (AOR = 1.156, 95% CI:1.091, 1.267), non-smoker patients (AOR = 0.854, 95% CI: 0.686, 0.935) significantly affected on the variable of interest. Similarly, alcohol intake, drug toxicity and baseline clinical WHO stages significantly affected for the development of tuberculosis in HIV-positive patients under treatment.
Conclusion: In this study, baseline CD4 cell count, female patients, non-opportunistic diseases, and non-smoking status were negatively associated with the development of TB, whereas age of patients, living without partners, patients with no education, patients with low adherence, bedridden and ambulatory patients were positively associated to the development of TB in HIV patients. The findings obtained in this study are important for both service providers and patients. More attention should be given to those positively associated variables to response variables. The regional health bureau should open TB/HIV co-infection subsections like ART sections in each hospital.
© 2022 Tegegne and Minwagaw.

Entities:  

Keywords:  HAART; HIV-positive people; TB development; binary logistic regression model

Year:  2022        PMID: 35313549      PMCID: PMC8934160          DOI: 10.2147/IJGM.S358517

Source DB:  PubMed          Journal:  Int J Gen Med        ISSN: 1178-7074


  23 in total

Review 1.  Epidemiology of tuberculosis and HIV: recent advances in understanding and responses.

Authors:  Neil A Martinson; Christopher J Hoffmann; Richard E Chaisson
Journal:  Proc Am Thorac Soc       Date:  2011-06

Review 2.  Tuberculosis associated mortality in a prospective cohort in Sub Saharan Africa: Association with HIV and antiretroviral therapy.

Authors:  Tumaini J Nagu; Said Aboud; Ramadhani Mwiru; Mecky I Matee; Martin Rao; Wafaie W Fawzi; Alimuddin Zumla; Markus J Maeurer; Ferdinand Mugusi
Journal:  Int J Infect Dis       Date:  2017-02-01       Impact factor: 3.623

3.  Risk factors for non-adherence among people with HIV-associated TB in Karnataka, India: A case-control study.

Authors:  T S Ranganath; S G Kishore; Ramakrishna Reddy; H J Deepak Murthy; B Vanitha; B N Sharath; Hemant Deepak Shewade; N Soma Shekar
Journal:  Indian J Tuberc       Date:  2021-03-11

4.  TB and HIV Epidemiology and Collaborative Service: Evidence from Ethiopia, 2011-2015.

Authors:  Yalemzewod Assefa Gelaw; Yibeltal Assefa; Ricardo J Soares Magalhaes; Minilik Demissie; Wegayehu Tadele; Pandji Wibawa Dhewantara; Gail Williams
Journal:  HIV AIDS (Auckl)       Date:  2020-12-03

5.  HIV/TB co-infection in mainland China: a meta-analysis.

Authors:  Lei Gao; Feng Zhou; Xiangwei Li; Qi Jin
Journal:  PLoS One       Date:  2010-05-20       Impact factor: 3.240

6.  Adherence to medications in systemic lupus erythematosus.

Authors:  Sri Koneru; Lakshmi Kocharla; Gloria C Higgins; Avis Ware; Murray H Passo; Yolanda D Farhey; Anne-Barbara Mongey; T Brent Graham; J Lawrence Houk; Hermine I Brunner
Journal:  J Clin Rheumatol       Date:  2008-08       Impact factor: 3.517

7.  HIV coinfections with tuberculosis among HIV-1 infected individuals in old cross river state, Nigeria.

Authors:  Iheanyi Omezuruike Okonko; Immaculate Ugochi Ejike; Chioma Innocent-Adiele; Tochi Ifeoma Cookey
Journal:  J Immunoassay Immunochem       Date:  2020-01-20

8.  Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.

Authors:  Kebede Embaye Gezae; Haftom Temesgen Abebe; Letekirstos Gebreegziabher Gebretsadik
Journal:  BMC Infect Dis       Date:  2019-02-04       Impact factor: 3.090

9.  Levels of Adherence and Associated Factors Among Children on ART Over Time in Northwest, Ethiopia: Evidence from a Multicenter Follow-Up Study.

Authors:  Fisha GebreEyesus; Dagninet Mitku; Tadesse Tarekegn; Bogale Temere; Tamene Terefe; Amsalu Belete; Getasew Legas; Dejen Feleke; Moges Gelaw Taye; Nega Baye; Fitalew Admasu; Enyew Dagnew; Tewachew Liyeh; Melkamu Jimma; Ermias Chanie
Journal:  HIV AIDS (Auckl)       Date:  2021-08-18

10.  Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.

Authors:  Kesetebirhan Delele Yirdaw; Degu Jerene; Zewdu Gashu; M E Edginton; Ajay M V Kumar; Yohannes Letamo; Beniam Feleke; Alula M Teklu; Solomon Zewdu; Bill Weiss; Andrea Ruff
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

View more
  1 in total

1.  Development and Validation of the Tuberculosis Risk Score for Smokers (TBRSS).

Authors:  Tengku Noor Farhana Tengku Khalid; Wan Mohd Zahiruddin Wan Mohammad; Nik Rosmawati Nik Husain; Razan Ab Samat
Journal:  Int J Environ Res Public Health       Date:  2022-06-07       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.